Case reports
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/kg nucleated cells was transfused on day 0. After drawal of post-tranplant immunosuppression or by engraftment chimeric analysis on day +24 revealed increasadministration of donor lymphocytes in an early phase ing autologous patterns until no donor hematopoiesis was of the development of relapse. We present the case detectable on day +70 ( Figure 1 ) when typical dysplastic reports of two children (MDS and AML) with rapidly cells and leukemic blasts with recurrence of monosomy 7 increasing MC in whom withdrawal of post-transplant were detected in the peripheral blood. Thereafter the disimmunosuppression or donor lymphocyte infusion ease was controlled by treatment with thioguanine until 10 (DLI) did prevent relapse. months after BMT. At that time leukocytes increased and Keywords: acute leukemia; hematopoietic chimerism; additional therapy with cytarabine (Ara-C) 20 mg/day for adoptive immunotherapy 5 days and hydroxyurea 250 mg/day was initiated. One year after the first transplantation, the patient was reconditioned with fractionated total body irradiation (TBI) (6 × 2 Gy), thiotepa 10 mg/kg, CY 120 mg/kg and antilymphocyte Although allogeneic BMT (allo-BMT) has been performed globulin (ALG) 30 mg/kg/day for 3 days. The boy was rewith increasing success in the situation of particular unfavinfused with 2.5 × 10 8 /kg nucleated bone marrow cells from orable acute leukemias in children over the last decades, the same donor on day 0. CsA was started at 3 mg/kg/day the outcome is mainly affected by relapse in this cohort of patients.
1 Treatment by which long-term remissions could be re-achieved is mainly restricted to additional marrow transplantation with a significantly increased rate of complications.
2,3 Recently we were able to demonstrate that patients with increasing amounts of autologous marrow repopulation (mixed chimerism MC) after allo-BMT have an increased risk (P = 0.0078) of developing relapse or graft rejection. 4 We subsequently asked whether treatment modalities, eg withdrawal of post-transplant immunosuppression or administration of donor lymphocytes on the basis of increasing MC in an early phase of recurrence of underlying disease, might prevent relapse. on day −3 as GVHD prophylaxis. Because of the onset of II. Prednisolone was added and the dose of CsA increased. With this regimen aGVHD was controlled and the adminisaGVHD, prednisolone was added on day +14 at 2 mg/kg/day. Under this therapy GVHD resolved. Followtration of prednisolone was stopped 10 days later. After engraftment on day +18, analysis of post-transplant chimering engraftment, chimeric analysis on day +23 showed 5% autologous signals increasing to 20% on day +30. Immunoism revealed MC with slightly increasing autologous patterns which increased up to 25% on day +54 in the periphsuppressive therapy was therefore discontinued. On day +35 dysplastic cells occurred in the peripheral blood; eral blood ( Figure 3 ). In the bone marrow MC with a 25% autologous marrow population was confirmed but MRD monosomy 7 was not detectable. In order to intensify a graft-versus-leukemia effect (GVL) 1 × 10 7 donor could not be detected at the time of evaluation. CsA was withdrawn on day +54. Although the patient did not lymphocytes/kg were transfused. In the time following the autologous cell population decreased over time; CC was develop aGVHD again, the amount of the autologous marrow population decreased step by step and the patient established on day +80 (Figure 2 ). When the patient developed aGVHD grade II on day +54, prednisolone was developed CC on day +80. Since then the patient has been doing well and has remained in CR with full donor restarted. GVHD responded to therapy which was withdrawn 14 days later. Further analysis of chimerism has been chimerism for 11 months. performed once a month. Autologous patterns were not detected again. At present the patient is in good clinical condition with limited cGVHD and has been in complete Method remission for 11 months.
Analysis of post-transplant chimerism was performed by amplification of VNTRs by a quantitative PCR approach Patient No. 2 as described recently. 5 In addition, while grafted with a sex mismatched donor in both patients the amplification of y The second patient, a 5-year-old boy with AML (M5a) with a t(9;11) translocation, received allo-BMT in first complete amplimers could be performed according to Witt and Erickson. 6 Precautions to avoid contamination were as follows: remission from an HLA-identical sibling donor. The MLC was negative. After conditioning with BU 16 mg/kg, CY amplification was always performed with recipient pretransplant and donor DNA as negative controls and at least 120 mg/kg the patient was transplanted with unmanipulated bone marrow containing 3.6 × 10 8 nucleated cells/kg on day three-post-transplant samples each time a new sample was investigated. 0. GVHD prophylaxis with CsA 3 mg/kg was started on day −3. After an uncomplicated post-transplant period the patient started to develop acute GVHD of the skin, stage Discussion
Relapse of leukemia after allogeneic BMT is the most important cause of treatment failure in children. In contrast to patients with chronic leukemias, 7, 8 where the success of adoptive immunotherapy by DLI has been clearly established, the question of whether patients with acute leukemias would benefit from such an immunotherapy remains open. [9] [10] [11] This might be explained in part by the experience -specific samples were anadecreased and he converted to CC on day +80. The amount of autologous DNA was as follows: on day +35 20%; on day +40 10-15%; on day 50 lyzed together with post-transplant samples. The patient developed increasing MC with 25% autologous recovery on day +54. The post-trans-10%; on day +57 10-15%; and on day +71 3%. Results from further monthly analyses until day +303 documented CC. MW = molecular plant immunosuppression was withdrawn and the patient converted to CC on day +80. MW = molecular weight marker. weight marker. We have presented the case reports of two children with 2462-2465. rapidly increasing MC after allo-BMT in whom by with- efficiently reduce the GVL reaction. 12, 13 In both patients it
